Biognosys Launches Spectronaut 20 and SpectroMine 5, Setting New Benchmarks in Immunopeptidomics
ZURICH and BOSTON, May 30, 2025 (GLOBE NEWSWIRE) — Biognosys, a global leader in mass spectrometry-based proteomics solutions, announces the launch of Spectronaut® 20 and SpectroMine™ 5 at the ASMS 2025 Annual Conference, taking place June 1–5 in Baltimore, MD. These major software updates mark significant technological advances in unspecific search performance, immunopeptidomics, and cloud-ready proteomics workflows.
At the core of the new releases is Kuiper, Biognosys' novel search engine, powered by proprietary prediction models specifically optimized for unspecific searches. Kuiper delivers record-breaking peptide identifications, especially for immunopeptidomics applications.
Key Features of Spectronaut® 20:
Kuiper also powers SpectroMine™ 5, Biognosys' latest release for DDA-based proteomics, now offering significantly enhanced identification performance. With newly added Linux support, SpectroMine joins Spectronaut in enabling high-throughput proteomics data analysis in cloud and high-performance computing (HPC) environments—enabling scalable, next-generation research workflows.
The applications of Biognosys' next-generation software will be highlighted through multiple scientific posters, two breakfast seminars, and workshop participations. These include two joint presentations with Greywolf Therapeutics on advanced immunopeptidomics workflows, as well as contributions to a workshop on best-practice reporting guidelines for DIA data.
Biognosys will also present its latest technological innovation, the P2 Enrichment System—a robust, nanoparticle-based plasma workflow offering unprecedented depth, reproducibility, and throughput in plasma proteomics. Originally introduced at ASMS 2024, the P2 system will be featured in a new scientific poster and in a presentation by collaborators from Johns Hopkins School of Medicine. Their research demonstrates P2's real-world application in a clinical study on circulating biomarker discovery for advancing early detection of neurodegenerative diseases.
In addition, Biognosys has been invited to deliver an oral presentation on Proteoverse® Digital Proteome, the company's proprietary multi-tissue, multi-species proteome expression atlas. As one of the most comprehensive resources of its kind it provides powerful insights into the proteomic landscape across human and preclinical species, supporting cutting-edge research in drug discovery and translational science.
'Immunopeptidomics is key to understanding how our therapeutics are making a difference for patients. Spectronaut 20 empowers us to leverage complex datasets with greater speed and depth, delivering critical insights into MHC-I antigen modulation and its effects on immune recognition,' said Daniel Green, Ph.D., Head of Bioinformatics at Greywolf Therapeutics.
'The P2 Enrichment System from Biognosys was seamlessly transferred to our lab at the Broad Institute. We were impressed by the clarity and robustness of the protocols, as well as the exceptional performance of the technology across our sample sets,' said Steven A. Carr, Ph.D., Senior Director of Proteomics and Institute Scientist at the Broad Institute of MIT and Harvard.
For more information on Biognosys' scientific presence at ASMS 2025, please visit:
https://biognosys.com/conferences/73rd-asms-conference-2025/
About Spectronaut®
Spectronaut is Biognosys' flagship data analysis software for data-independent acquisition (DIA) mass spectrometry (MS) based proteomics. The software employs advanced Search and Artificial Intelligence (AI) algorithms to translate data into actionable insights for life science research. Spectronaut enables reproducible and precise quantification of thousands of proteins in a single experiment and provides multi-dimensional insights into protein expression, function, and structure across all major biological species and sample types. For more information, visit
www.spectronaut.com
About Biognosys
Biognosys is a leading contract research organization (CRO) specializing in proteomics services for early-stage R&D through clinical trial biomarker monitoring. Partnering with the most innovative biotech and pharmaceutical companies worldwide, Biognosys utilizes unique, patented technologies and high-resolution mass spectrometry to quantify thousands of proteins with unmatched precision, depth, and throughput. With laboratories near Zuerich, Switzerland and Boston, Massachusetts, Biognosys combines scientific expertise and next-generation proteomics to accelerate drug discovery and development, and supports translational and preclinical research, and clinical trials for precision medicine. Learn more at
www.biognosys.com
Media Contacts
Kristina Beeler, Ph.D.
Chief Product Development and Marketing Officer
kristina.beeler@biognosys.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
43 minutes ago
- Business Upturn
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic adenocarcinoma 1 Post-hoc analysis of NAPOLI 3 study determined characteristics associated with long-term survival, with median overall survival of 19.5 months amongst long-term survivors receiving Onivyde ® plus oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) regimen as a first-line therapy 2 Dose reductions and/or treatment delays for the management of adverse events enabled patients to stay on treatment longer and achieve high cumulative doses of liposomal irinotecan and oxaliplatin 2 PARIS, France, 31 May 2025 – Late-breaking (LBA4175) post-hoc analysis data from the Phase III NAPOLI 3 study were presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These results found a median overall survival (mOS) of 19.5 months among long-term survivors (n=15) with metastatic pancreatic adenocarcinoma (mPDAC) treated with the Onivyde ® (irinotecan liposome injection) plus oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) regimen as a first-line treatment (n=120), with younger age at diagnosis, and certain tumor and metastasis locations associated with long-term survivorship. 2 Pancreatic adenocarcinoma (PDAC) is the most common type of cancer that forms in the pancreas, with more than 60,000 people diagnosed annually in the U.S. and nearly 500,000 people globally.3 , 4 It is often detected after the disease has spread to other parts of the body (metastatic or stage IV)5 and fewer than 20% of people diagnosed with metastatic pancreatic adenocarcinoma (mPDAC) survive longer than one year. 5 , 6 Overall, pancreatic cancer has the lowest five-year survival rate of all cancer types globally and in the U.S. 5 , 6 'When people are diagnosed with metastatic pancreatic adenocarcinoma, the most important question remains: how long will they have with their loved ones,' said Dr. Vincent Chung, Medical Oncologist, City of Hope. 'Findings from the NAPOLI 3 post-hoc analysis provide important context on long-term overall survival with the Onivyde (NALIRIFOX) treatment regimen.' The analysis included patients who survived for 18 months or longer (N=15), with findings showing long-term survivors living with mPDAC had a mOS of 19.5 months (interquartile range [IQR]: 18.8–22.6). 2 Clinical and pathological factors of long-term survivors included younger than average age at time of diagnosis (median age 61.0 (IQR: 49.0–70.5) as well as tumor location. 2 Fewer patients had tumors in the head or tail of the pancreas (53.3% had the main pancreatic tumor located in the body of the pancreas), a substantial proportion had liver metastasis (66.7%) and ≥3 metastatic sites (53.3%). 2 Additionally, findings indicate dose reduction and treatment delays resulted in prolonged exposure and higher cumulative doses of the Onivyde (NALIRIFOX) regimen. 1 Liver metastasis and ≥3 metastatic sites, dose modifications and an otherwise good clinical profile enabled people to achieve a long mOS. 2 Consideration should be taken when interpreting these results as a post-hoc analysis with a small sample size. 'Data from the Phase III NAPOLI 3 trial were the first positive data of its kind in a decade and continue to reinforce the potential for long-term outcomes with the Onviyde (NALIRIFOX) regimen,' said Sandra Silvestri, MD, PhD, Executive Vice President, Chief Medical Officer, Ipsen. 'With people on average living just 4-6 months following diagnosis with pancreatic adenocarcinoma, these data help us to understand the characteristics associated with long-term survival seen in the NAPOLI trial, an important advancement for this difficult-to-treat cancer where data of this kind are scarce.' ENDS About Onivyde (irinotecan liposome injection) Onivyde is a long-circulating liposomal topoisomerase inhibitor. In Onivyde, irinotecan is enclosed in tiny fat particles called liposomes which accumulate in the tumor and release slowly over time. Onivyde is administered via intravenous infusion over 90 minutes every two weeks with recommendations on dosing modifications. Onivyde, as part of the NALIRIFOX regimen (combined with oxaliplatin, fluorouracil (FU) and leucovorin (LV)), is for people living with mPDAC who are treatment naïve or used in combination with FU and LV following gemcitabine-based therapy. Onivyde is not indicated as a single agent for the treatment of adult patients with metastatic pancreatic adenocarcinoma. Ipsen has exclusive commercialization rights for the current and potential future indications for Onivyde in the U.S. Servier, an independent international pharmaceutical company governed by a foundation and with an international presence in 140 countries, is responsible for the commercialization of Onivyde outside of the U.S., Taiwan and Canada. PharmaEngine is a commercial stage oncology company headquartered in Taipei and is responsible for the commercialization of Onivyde in Taiwan. About NAPOLI 3 Study NAPOLI 3 is a randomized, open-label Phase III trial of an Onivyde treatment regimen (NALIRIFOX) in treatment-naïve mPDAC. NAPOLI 3 enrolled 770 patients across 187 trial site locations in 18 countries across Europe, North America, South America, Asia, and Australia. Patients were randomized to receive Onivyde plus oxaliplatin, fluorouracil and leucovorin (NALIRIFOX regimen; n=383) twice in a month (days 1 and 15 of 28-day cycle) compared to an injection of nab-paclitaxel and gemcitabine (n=387) administered three times a month (days 1, 8, 15 of a 28-day cycle) . About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit Ipsen Media contacts Investors Khalid Deojee | +33 666019526 | [email protected] Media Disclaimers and/or Forward-Looking Statements The forward-looking statements, objectives and targets contained herein are based on Ipsen's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including Ipsen's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen's activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen's partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen's business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen's latest Universal Registration Document, available on References 1 Wainberg et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023 Oct 7;402(10409):1272-1281. 2 Chung et al. NAPOLI 3 phase 3 study of NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): final overall survival (OS) analysis and characteristics of the long-term survivors. As presented at ASCO Congress 2025 Chicago, USA 3 American Cancer Society – Cancer Facts and Figures 2024. Available : 4 5 Orth, M., Metzger, P., Gerum, S. et al. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol 14, 141 (2019). Attachment Ipsen PR_ASCO NAPOLI_31052025 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Time Business News
5 hours ago
- Time Business News
Decoding Consumer Behavior: Marpany's AI Advertising Analysis for 5.3x ROAS
Introduction: 'Data is useless without insight – this is where AI revolutionizes advertising.' While businesses drown in analytics, artificial intelligence is the lifeline that transforms numbers into actionable intelligence. At Marpany, we pioneer AI advertising and analysis that predicts campaign success before launch, identifies micro-trends competitors miss, and turns every dollar into measurable growth. Through proprietary machine learning models processing 2.3 million data points hourly, we deliver the predictive ad performance insights Fortune 500 brands trust. Discover how our award-winning approach moves beyond reactive reporting to proactively shape marketing strategy – and why clients like LuxeAuto achieved 40% lower CPA in 90 days. AI doesn't just optimize ads – it deciphers the why behind every click and conversion. Blind spots: 68% of customer journeys cross 3+ devices (untracked by last-click models) Lag time: Manual reports arrive 7-10 days post-campaign Surface-level: Metrics like 'impressions' reveal nothing about purchase intent Marpany's INSIGHT Engine™ forecasts outcomes with 92% accuracy by analyzing: Historical conversion patterns Seasonality trends Real-time market sentiment Example: Predicted Q4 CPG demand surge 11 days early, saving $220K in wasted spend Our NLP models scan 50K+ daily social mentions to quantify: Emotional sentiment (joy/frustration ratios) Emerging complaint themes Competitor weakness opportunities Impact: Beverage brand increased positive sentiment 37% in 6 weeks AI processes data in 3-second cycles: Ingest: Consolidates paid/organic/social/email metrics Cluster: Groups users by behavioral fingerprints Predict: Scores conversion probability per segment Our multi-touch AI attribution: Values each touchpoint by influence weight Credits offline conversions via geo-fenced campaigns Adjusts model weekly based on new patterns Results from Marpany clients: KPI Pre-AI Post-AI ROAS 2.1x 5.3x CPA $89 $52 Test Efficiency 14 days 38 mins AI detected these before human teams: 22% spike in 'sustainable packaging' searches (3 weeks pre-trend) Gen Z abandoning Instagram Reels for TikTok EDU content Price sensitivity thresholds shifting by income bracket Our solution: AI filtration: Automatically discards irrelevant 73% of data Anomaly detection: Flags statistically significant changes Automated summaries: Delivers 1-page 'executive insight' reports Marpany's Unified Data Hub: Connects 120+ platforms via API Resolves user identities across devices Complies with CCPA/GDPR through zero-party data protocols Soon: 'What-if' simulators for budget reallocations Creative fatigue prediction alerts Competitor response forecasting 2025 innovations: In-store cam analytics + mobile ad triggers Voice assistant mood detection for ad tone Smart TV viewership → retargeting flows Challenge: $1.2M monthly ad waste from misattributed conversions Marpany Solution: Deployed predictive CPA modeling Built real-time creative fatigue alerts Automated budget shifts via IBM Watson-integrated platform Results in 90 Days: 40% lower CPA 28% higher customer LTV $3.8M annualized savings CTA: Stop guessing – start predicting. Book your AI Advertising Analysis Audit and receive a free Predictive ROI Projection Report within 48 hours. TIME BUSINESS NEWS
Business Insider
5 hours ago
- Business Insider
Infinix wins ‘User-Friendly Smartphone Brand of the Year' at Beacon of ICT Awards 2025
Infinix Nigeria has been named 'User-Friendly Smartphone Brand of the Year' at the prestigious 16th Africa Beacon of ICT (BoICT) Awards, held in Lagos on May 24, 2025. The award celebrates Infinix's standout approach to innovation, intuitive design, and accessible pricing that resonates with Africa's growing youth market. This recognition reflects Infinix's continued commitment to innovation, performance, and excellent product design, all offered at competitive prices that meet the evolving needs of today's users. Speaking on the recognition, Yemisi Ode, Marketing Communications & PR Manager, Infinix Nigeria, highlighted that, ' this award reaffirms our mission to empower today's youth with devices that blend cutting-edge innovation and everyday usability. Our devices are designed to elevate the lifestyle and creativity of our users''. This award follows the successful launch of the Infinix NOTE 50 Series, a lineup that redefines mid-range smartphones by integrating flagship-level design and intelligent features. With its combination of premium materials like the ArmorAlloy™ metal frame, and cutting-edge One-Tap AI functionalities, the NOTE 50 Series exemplifies Infinix's commitment to delivering high-performance, user-centric smartphones that cater to the evolving needs of today's consumers, a core value echoed in this BoICT recognition. The BoICT Awards, organized by Communications Week Media Limited, celebrates the contribution of leading individuals and organisations in technology driving digital transformation and excellence in Africa's ICT ecosystem. According to Ken Nwogbo, Founder and Editor-in-Chief of Communications Week, the awards are designed not only to recognize achievements but also to encourage ongoing innovation in the industry. Infinix has consistently delivered cutting-edge smart devices that combine style with next-level technology. This recent win is a testament to its reputation as a brand that continues to push the boundaries of what mid-range smartphones can deliver. Guided by its brand essence 'The Future Is Now' Infinix continues to empower its users to lead intelligent, connected lives.
